Filing Analysis
Cingulate Inc. announced that the USPTO has issued U.S. Patent No. 12,653,791, which covers the formulation and method of use for its product CTx-1301.
📋 Key Facts
- U.S. Patent No. 12,653,791 was issued on June 16, 2026.
- The patent covers key aspects of CTx-1301's formulation and method of use.
- The patent protection extends through December 2042.
Cingulate Inc. received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for CTx-1301 for the treatment of ADHD. While the FDA did not raise concerns regarding clinical safety or efficacy, it requested additional Chemistry, Manufacturing and Controls (CMC) information.
🚩 Red Flags
- FDA CRLs are significant setbacks for micro-cap biotech companies as they delay commercialization and revenue generation.
- CMC issues can sometimes be more complex and time-consuming to resolve than clinical data gaps, depending on the nature of the manufacturing deficiency.
📋 Key Facts
- FDA issued a Complete Response Letter (CRL) on June 2, 2026, for CTx-1301 (dexmethylphenidate HCl).
- The CRL specifically identifies requests for Chemistry, Manufacturing and Controls (CMC) information.
- The FDA did not raise concerns regarding the clinical safety or efficacy of the drug.
- The company intends to promptly resubmit the requested information to the FDA.
Cingulate Inc. announced that Class II directors Jeff Ervin and Jay Roberts will not seek re-election at the 2026 Annual Meeting in an effort to reduce the board size to five members. Additionally, Jeff Hargroves transitioned from a Class I to a Class II director to maintain balanced board classes.
🚩 Red Flags
- Board downsizing can sometimes indicate underlying financial distress or pressure to cut SG&A expenses.
📋 Key Facts
- Class II directors Jeff Ervin and Jay Roberts are not seeking re-election at the 2026 Annual Meeting.
- The Board of Directors will be reduced to five members on the date of the Annual Meeting.
- A new Board chairman will be appointed at the Annual Meeting.
- Jeff Hargroves resigned as a Class I director and was immediately re-appointed as a Class II director on May 18, 2026, to satisfy class-size requirements.
Cingulate Inc. reported its financial results for the first quarter ended March 31, 2026, and provided a business update via a press release.
📋 Key Facts
- Financial results cover the quarter ended March 31, 2026
- Press release is furnished as Exhibit 99.1
- The filing was signed by Jennifer L. Callahan, Chief Financial Officer
- The company is classified as an emerging growth company
Cingulate Inc. appointed Zhanpeng “Frederick” Jiang to its Board of Directors as a Class I director, effective March 27, 2026. The appointment follows stockholder approval of an Issuance Proposal and is tied to a previously disclosed securities purchase agreement dated January 28, 2026.
🚩 Red Flags
- The director's appointment is subject to the terms of a 'securities purchase agreement' dated January 28, 2026, suggesting the seat may be a condition of a financing arrangement.
📋 Key Facts
- Zhanpeng “Frederick” Jiang was appointed as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders.
- Mr. Jiang was appointed to the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Compensation includes an annual cash retainer of $40,000 plus additional fees for committee service ($7,500 for Audit, $5,000 for Compensation, $4,000 for Nominating).
- Mr. Jiang was granted an option to purchase 15,000 shares of common stock, vesting in two equal installments over one year.
- The Board determined Mr. Jiang meets the independence requirements of Nasdaq Listing Rule 5605.
Cingulate Inc. entered into a $100 million at-the-market (ATM) equity offering agreement and received shareholder approval for the issuance of shares related to a previous private placement of preferred stock and warrants.
🚩 Red Flags
- Significant potential dilution from a $100 million ATM facility relative to micro-cap valuation.
- Approval of common stock issuance for Series A Preferred Stock and warrants indicates further impending dilution.
- Multiple 8-K items (1.01 and 5.07) reported in a single filing.
📋 Key Facts
- Entered into an ATM Sales Agreement with A.G.P./Alliance Global Partners on March 24, 2026.
- The ATM agreement allows for the sale of common stock for aggregate gross proceeds of up to $100,000,000.
- The company will pay a 3.0% commission to A.G.P. on gross proceeds from sales.
- Stockholders approved the issuance of common stock upon conversion of Series A Convertible Preferred Stock and warrants from a January 27, 2026 agreement.
- The stockholder approval was required to comply with Nasdaq Listing Rule 5635(b).
Cingulate Inc. reported its full-year 2025 financial results and announced a significant intellectual property milestone for its lead ADHD candidate, CTx-1301.
📋 Key Facts
- The company announced financial results for the fiscal year ended December 31, 2025, on March 18, 2026.
- The USPTO issued a Notice of Allowance on March 17, 2026, for a patent application covering lead asset CTx-1301 (dexmethylphenidate).
- The new patent protection for CTx-1301 is expected to extend through May 2042.
- CTx-1301 is being developed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).